rethinkTHC Search
Menu
Study breakdown

CBD reversed amphetamine-induced brain damage in a rat model of mania

Animal StudyPreliminary evidence
The takeaway

CBD reversed oxidative brain damage caused by amphetamine in rats and increased BDNF, a protein important for brain cell health, suggesting mood-stabilizing potential.

Read this if you follow CBD research and want to understand its potential role in brain protection.

CBD increased BDNF, a key protein for brain cell health

What the researchers found

Researchers used two experimental models in rats. In the reversal model, rats received amphetamine daily for 14 days (to mimic mania), then received CBD (15, 30, or 60 mg/kg) from day 8 to 14. In the prevention model, CBD was given first, followed by amphetamine from day 8 to 14.

In the reversal model, CBD at 15 mg/kg reversed amphetamine-induced oxidative damage in the hippocampus and increased brain-derived neurotrophic factor (BDNF) at 30 mg/kg. In the prevention model, CBD at 30 or 60 mg/kg prevented oxidative protein damage in the prefrontal cortex, and all CBD doses prevented damage in the hippocampus and striatum.

Notably, CBD did not reduce amphetamine-induced hyperactivity in either model, suggesting its neuroprotective effects were independent of behavioral changes.

Why it matters

Bipolar disorder involves oxidative stress and reduced BDNF in the brain. If CBD can protect against these changes, it might function as a neuroprotective adjunct to standard mood stabilizers, addressing brain health rather than just symptom control.

The numbers in context

CBD 15 mg/kg reversed hippocampal oxidative damage. CBD 30 mg/kg increased BDNF. CBD 30-60 mg/kg prevented prefrontal cortex damage. All doses (15, 30, 60 mg/kg) prevented hippocampal and striatal damage in the prevention model.

How the study worked

Two rat models of mania: reversal (CBD given during ongoing amphetamine) and prevention (CBD given before amphetamine). CBD at 15, 30, and 60 mg/kg was administered twice daily. Oxidative damage markers, BDNF levels, and locomotor activity were measured.

What this study cannot tell us

Amphetamine-induced hyperactivity is a limited model of bipolar mania. CBD did not reduce hyperactivity, raising questions about behavioral relevance. Rat brain responses may not translate to human bipolar disorder. Dosing and timing may not apply clinically.

How to read the evidence

Animal study using a pharmacological model of mania. Provides mechanistic data but limited clinical applicability. Multiple dose levels and two models strengthen internal validity.

When this study was published

Published in 2011. CBD research for mood disorders has continued, with some small clinical trials conducted since.

The bigger picture

Standard mood stabilizers (lithium, valproate) also have neuroprotective properties. The finding that CBD shares some of these properties opened questions about whether it could complement existing treatments, particularly in protecting against the brain damage associated with manic episodes.

Questions still open

  • Why did CBD protect brain cells without affecting behavior? Could CBD be useful as an adjunct to mood stabilizers for neuroprotection? What is the clinical significance of BDNF increases from CBD?

Common questions

Could CBD treat bipolar disorder?
This rat study showed CBD protected against brain damage in a model of mania, but it did not reduce manic-like behavior. CBD may have neuroprotective value rather than direct mood-stabilizing effects. Human clinical data is very limited.
What is BDNF and why does it matter?
Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival and growth of brain cells. Low BDNF levels are associated with depression and bipolar disorder. CBD's ability to increase BDNF in this study suggested a neuroprotective mechanism.

Read the original research

Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.

Journal of psychopharmacology (Oxford, England), 25(2), 274-80

Citation

Valvassori, Samira S; Elias, Guilherme; de Souza, Bruna; Petronilho, Fabrícia; Dal-Pizzol, Felipe; Kapczinski, Flávio; Trzesniak, Clarissa; Tumas, Vitor; Dursun, Serdar; Chagas, Marcos Hortes Nisihara; Hallak, Jaime E C; Zuardi, Antonio W; Quevedo, João; Crippa, José A S. (2011). Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.. Journal of psychopharmacology (Oxford, England), 25(2), 274-80. https://doi.org/10.1177/0269881109106925

Explore the wider topic